Bristol-Myers Squibb Company

BMY

US1101221083

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Employees

34,100

Sector

Pharmaceuticals

Calendar

2025-02-06 - Q4 2024 Earnings Release

More about the company

Income Statement and Estimates

income-statement-evolution-chart BRISTOL-MYERS-SQUIBB-COMP

More financial data

Analysis / Opinion

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 01:06 pm

More Strategies

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

55.78USD

Average target price

60.58USD

Spread / Average Target

+8.60%

Consensus

Profit revisions

estimates-change-chart BRISTOL-MYERS-SQUIBB-COMP

Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart BRISTOL-MYERS-SQUIBB-COMP

Company calendar

Market Closed - Nyse Other stock markets 16:00:02 2024-12-13 EST			5-day change	1st Jan Change
55.78 ^USD	-0.89%		-6.06%	+8.71%

12-13	Bristol-Myers Squibb Files Mixed Shelf	MT
12-12	Bristol Myers: increase in quarterly dividend	CF

Bristol-Myers Squibb Files Mixed Shelf	12-13	MT
Bristol Myers: increase in quarterly dividend	12-12	CF
Agilent Cancer Diagnostic Assay Receives Certification to Comply with New EU Regulations	12-10	MT
Berenberg Raises Price Target on Bristol-Myers Squibb to $60 From $55, Keeps Hold Rating	12-10	MT
Bristol Myers Squibb Highlights Progress of Cell Therapy Portfolio At Ash 2024 with Long-Term Survival Data and Results from Expanding Pipeline	12-09	CI
Nuvig Therapeutics, Inc. announced that it has received $161 million in funding from a group of investors	12-04	CI
Bristol-Myers Seeks Bolt-On Acquisitions	12-03	CI
Bristol-Myers Squibb Company Presents at Citi's 2024 Global Healthcare Conference, Dec-03-2024 08:00 AM	12-03
AI Proteins, Inc. Announces Research Collaboration and Option Agreement with Bristol Myers Squibb for Miniprotein-Based Therapeutics Valued Up to $400 Million	12-03	CI
Astrazeneca's Enhertu, Orpathys Among 91 Drugs Added to China's National Reimbursement Drug List	11-29	MT
Bernstein Adjusts Price Target on Bristol-Myers Squibb to $62 From $56, Keeps Market Perform Rating	11-25	MT
Wall Street warms to AI's glow	11-22
Bristol Myers: presents new data to ASH	11-19	CF
Bristol Myers Squibb?s Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms	11-19	CI
Bristol-Myers Squibb Company Presents at Jefferies London Healthcare Conference 2024, Nov-19-2024 09:30 AM	11-19
Wells Fargo Adjusts Price Target on Bristol-Myers Squibb to $60 From $52, Maintains Equalweight	11-18	MT
HSBC Adjusts Bristol-Myers Squibb Price Target to $58 From $50, Maintains Hold Rating	11-15	MT
Bristol-Myers Says European Committee Recommends Approval of Opdivo-Yervoy Combination Therapy for Colorectal Cancer	11-15	MT
Bristol Myers Squibb's Augtyro Recommended for EU Approval	11-15	MT
Bristol Myers: positive opinion from CHMP for Opdivo	11-15	CF
Bristol Myers Gets CHMP Backing for Augtyro Cancer Drug	11-15	DJ
Bristol-Myers Says European Committee Recommends Approval of Repotrectinib	11-15	MT
Bristol Myers: positive opinion for repotrectinib in U	11-15	CF
Bristol-Myers Squibb Faces $6.7 Billion Lawsuit in Renewed Cancer Drug Delay Case	11-15	MT
Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors	11-15	CI

Bristol-Myers Squibb Company

Equities

BMY